Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth

Dll4, one of the Notch ligands, is overexpressed in ovarian cancer, especially in tumors resistant to anti–VEGF therapy. Here, we examined the biological effects of dual anti-Dll4 and anti-VEGF therapy in ovarian cancer models. Using Dll4-Fc blockade and anti-Dll4 antibodies (murine REGN1035 and hum...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Cancer Ther
Päätekijät: Huang, Jie, Hu, Wei, Hu, Limin, Previs, Rebecca A., Dalton, Heather J., Yang, Xiao-Yun, Sun, Yunjie, McGuire, Michael, Rupaimoole, Rajesha, Nagaraja, Archana S, Kang, Yu, Liu, Tao, Nick, Alpa M., Jennings, Nicholas B., Coleman, Robert L., Jaffe, Robert B., Sood, Anil K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893925/
https://ncbi.nlm.nih.gov/pubmed/27009216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-15-0144
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia